Biocon (BIOCON) Q4 24/25 earnings summary

Executive summary

• Achieved strong growth across generics, biosimilars, and research services, with robust launches and global expansion in FY2025.

• Notable product launches included Liraglutide in the U.K., Lenalidomide and Dasatinib in the U.S., and Yesintek (biosimilar Ustekinumab) in the U.S.

• Syngene acquired a biologics manufacturing facility in the U.S., expanding CDMO capabilities.

• Audited standalone and consolidated financial results for FY25 approved, with unqualified audit opinions and no modifications by auditors.

• Final dividend of Rs. 0.50 per equity share recommended, subject to shareholder approval.

Financial highlights

• Q4 operating revenue reached INR 4,417 crore, up 15% year-over-year and 16% sequentially on a like-for-like basis.

• FY2025 consolidated revenue at Rs. 1,64,699 million, up from Rs. 1,56,212 million in FY24.

• Q4 core EBITDA was INR 1,363 crore (16% YoY growth), with a 31% margin; reported EBITDA was INR 1,115 crore.

• FY2025 net profit was INR 1,013 crore; consolidated net profit at Rs. 14,294 million, aided by exceptional gains.

• Exceptional gain of Rs. 6,075 million in standalone results from sale of Syngene shares.

Segment performance

• Generics FY2025 revenue: INR 3,017 crore, up 8% YoY; EBITDA margin at 12%.

• Biosimilars FY2025 revenue: INR 9,017 crore, up 15% YoY; four biosimilars exceeded $200 million in sales.

• Research services (Syngene) FY2025 revenue: INR 3,642 crore, up 4% YoY; EBITDA margin at 30%.

• Biosimilars and Research Services remain key contributors to consolidated revenue and profit.

• Sale of Metabolics, Oncology, and Critical Care business to Eris Lifesciences for Rs. 12,420 million, resulting in a gain of Rs. 10,573 million.